PCSK9 and atherosclerosis: In addition, the substantially low achievement rate of LDL reduction, similarly reported in the previous investigations, indicates that new therapies such as PCSK9 inhibitors may provide an opportunity to reduce the burden of cardiovascular events among the very high ASCVD population [29, 30].